| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Lillian Jan Findlay, Peggy El-Mallakh, Rif S El-Mallak. Management of bipolar I depression: clinical utility of lurasidone. Therapeutics and clinical risk management. vol 11. 2015-01-22. PMID:25609973. |
management of bipolar i depression: clinical utility of lurasidone. |
2015-01-22 |
2023-08-13 |
human |
| Lillian Jan Findlay, Peggy El-Mallakh, Rif S El-Mallak. Management of bipolar I depression: clinical utility of lurasidone. Therapeutics and clinical risk management. vol 11. 2015-01-22. PMID:25609973. |
lurasidone is a new option for the treatment of bipolar depression with relatively few side effects. |
2015-01-22 |
2023-08-13 |
human |
| Cecilio Alamo, Francisco López-Muñoz, Pilar García-Garcí. The effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorder. Expert review of neurotherapeutics. vol 14. issue 6. 2015-01-13. PMID:24779382. |
lurasidone was approved in 2010 for the treatment of schizophrenia and recently, 2013, for bipolar depression in monotherapy and an adjunct to lithium or valproate. |
2015-01-13 |
2023-08-13 |
Not clear |
| Susan L McElro. Pros and cons of approved therapies for bipolar depression and ongoing unmet needs. The Journal of clinical psychiatry. vol 75. issue 10. 2015-01-12. PMID:25373131. |
olanzapine-fluoxetine combination, quetiapine, and lurasidone are the only fda-approved treatments for bipolar depression. |
2015-01-12 |
2023-08-13 |
Not clear |
| Leslie Citrome, Terence A Ketter, Josephine Cucchiaro, Antony Loebe. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of affective disorders. vol 155. 2014-09-17. PMID:24246116. |
clinical assessment of lurasidone benefit and risk in the treatment of bipolar i depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. |
2014-09-17 |
2023-08-12 |
Not clear |
| Leslie Citrome, Terence A Ketter, Josephine Cucchiaro, Antony Loebe. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of affective disorders. vol 155. 2014-09-17. PMID:24246116. |
prior to recent fda approval of lurasidone for treatment of bipolar depression there were only two approved treatments for this condition (quetiapine and olanzapine-fluoxetine combination), and these were as likely to provide therapeutic benefit as adverse effects. |
2014-09-17 |
2023-08-12 |
Not clear |
| Young Sup Woo, Hee Ryung Wang, Won-Myong Bah. Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatric disease and treatment. vol 9. 2014-06-24. PMID:24143101. |
lurasidone is a benzisothiazol derivative and an atypical antipsychotic approved by the us food and drug administration for the acute treatment of adults with schizophrenia (october 2010) and bipolar 1 depression (june 2013). |
2014-06-24 |
2023-08-12 |
Not clear |
| Young Sup Woo, Hee Ryung Wang, Won-Myong Bah. Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatric disease and treatment. vol 9. 2014-06-24. PMID:24143101. |
in two large, well-designed, 6-week trials in adult patients with bipolar 1 depression, lurasidone monotherapy and adjunctive therapy with mood stabilizers were significantly more effective than placebo at improving depressive symptoms assessed using the montgomery-Åsberg depression rating scale total score. |
2014-06-24 |
2023-08-12 |
Not clear |
| Young Sup Woo, Hee Ryung Wang, Won-Myong Bah. Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatric disease and treatment. vol 9. 2014-06-24. PMID:24143101. |
in both trials, lurasidone also reduced the clinical global impression-bipolar severity depression score to a greater extent than placebo. |
2014-06-24 |
2023-08-12 |
Not clear |
| Antony Loebel, Josephine Cucchiaro, Robert Silva, Hans Kroger, Jay Hsu, Kaushik Sarma, Gary Sach. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. The American journal of psychiatry. vol 171. issue 2. 2014-04-03. PMID:24170180. |
lurasidone monotherapy in the treatment of bipolar i depression: a randomized, double-blind, placebo-controlled study. |
2014-04-03 |
2023-08-12 |
Not clear |
| Antony Loebel, Josephine Cucchiaro, Robert Silva, Hans Kroger, Kaushik Sarma, Jane Xu, Joseph R Calabres. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. The American journal of psychiatry. vol 171. issue 2. 2014-04-03. PMID:24170221. |
lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar i depression: a randomized, double-blind, placebo-controlled study. |
2014-04-03 |
2023-08-12 |
Not clear |
| Antony Loebel, Josephine Cucchiaro, Robert Silva, Hans Kroger, Kaushik Sarma, Jane Xu, Joseph R Calabres. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. The American journal of psychiatry. vol 171. issue 2. 2014-04-03. PMID:24170221. |
the authors investigated the efficacy of lurasidone, a novel antipsychotic agent, as adjunctive therapy with lithium or valproate for the treatment of bipolar i depression. |
2014-04-03 |
2023-08-12 |
Not clear |
| Antony Loebel, Josephine Cucchiaro, Robert Silva, Hans Kroger, Kaushik Sarma, Jane Xu, Joseph R Calabres. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. The American journal of psychiatry. vol 171. issue 2. 2014-04-03. PMID:24170221. |
similarly, lurasidone treatment resulted in significantly greater endpoint reduction in cgi-bp depression severity scores compared with placebo (-1.96 versus -1.51; effect size=0.36) as well as significantly greater improvement in anxiety symptoms and in patient-reported measures of quality of life and functional impairment. |
2014-04-03 |
2023-08-12 |
Not clear |
| Alessia Luoni, Sjoerd Hulsken, Greta Cazzaniga, Giorgio Racagni, Judith R Homberg, Marco A Riv. Behavioural and neuroplastic properties of chronic lurasidone treatment in serotonin transporter knockout rats. The international journal of neuropsychopharmacology. vol 16. issue 6. 2014-01-15. PMID:23164505. |
the adaptive changes set in motion by repeated treatment with lurasidone may in fact contribute to the amelioration of functional capacities, closely associated with neuronal plasticity, which are deteriorated in patients with schizophrenia, bipolar disease and major depression. |
2014-01-15 |
2023-08-12 |
rat |
| Lindsay N Cates, Amanda J Roberts, Salvador Huitron-Resendiz, Peter B Hedlun. Effects of lurasidone in behavioral models of depression. Role of the 5-HT₇ receptor subtype. Neuropharmacology. vol 70. 2013-11-26. PMID:23416039. |
effects of lurasidone in behavioral models of depression. |
2013-11-26 |
2023-08-12 |
mouse |
| Lindsay N Cates, Amanda J Roberts, Salvador Huitron-Resendiz, Peter B Hedlun. Effects of lurasidone in behavioral models of depression. Role of the 5-HT₇ receptor subtype. Neuropharmacology. vol 70. 2013-11-26. PMID:23416039. |
we have tested lurasidone in both acute and chronic mouse models of depression. |
2013-11-26 |
2023-08-12 |
mouse |
| Rif S El-Mallakh, Ahmed Z Elmaadawi, Yonglin Gao, Kavita Lohano, R Jeannie Robert. Current and emerging therapies for the management of bipolar disorders. Journal of central nervous system disease. vol 3. 2013-07-17. PMID:23861648. |
these include eslicarbazepine, cariprazine, mem-1003, memantine, tamoxifen and pentazocine for acute mania; pramipexole, modafinil, armodafinil, divalproex, lurasidone, agomelatine, cariprazine, lisedexamfetamine, riluzole, rg-2417, bifeprunox, ropinirole, gsk1014802, and magnetic stimulation for bipolar depression; and asenapine, lurasidone, and cariprazine for relapse prevention. |
2013-07-17 |
2023-08-12 |
Not clear |
| Roger S McIntyre, Danielle S Cha, Mohammad Alsuwaidan, Diane McIntosh, Alissa M Powell, Jeanette M Jerrel. A review of published evidence reporting on the efficacy and pharmacology of lurasidone. Expert opinion on pharmacotherapy. vol 13. issue 11. 2012-11-07. PMID:22559286. |
controlled trials are currently underway to evaluate lurasidone's efficacy in bipolar depression as well as its procognitive effects in individuals with schizophrenia. |
2012-11-07 |
2023-08-12 |
Not clear |
| Norio Yasui-Furukor. Update on the development of lurasidone as a treatment for patients with acute schizophrenia. Drug design, development and therapy. vol 6. 2012-08-27. PMID:22675261. |
lurasidone treatment produced improvements in montgomery-asberg depression rating scale scores at 6 weeks that were significantly greater than placebo. |
2012-08-27 |
2023-08-12 |
human |
| Ludovic Samalin, Marion Garnier, Pierre-Michel Llorc. Clinical potential of lurasidone in the management of schizophrenia. Therapeutics and clinical risk management. vol 7. 2011-07-14. PMID:21753886. |
other therapeutic perspectives of lurasidone are assessed here, in particular bipolar depression. |
2011-07-14 |
2023-08-12 |
Not clear |